Impact of platelet transfusion refractoriness in the first 30 days post-hematopoietic stem cell transplantation on outcomes of patients with myelodysplastic syndrome
| Autor: | Yuanfeng Zhang, Yan Wang, Runzhi Ma, Li Liu, Jiali Sun, Xin Chen, Donglin Yang, Aiming Pang, Rongli Zhang, Qiaoling Ma, Weihua Zhai, Yi He, Jialin Wei, Tingting Zhang, Erlie Jiang, MingZhe Han, Sizhou Feng |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2024 |
| Předmět: | |
| Zdroj: | Frontiers in Immunology, Vol 15 (2024) |
| Druh dokumentu: | article |
| ISSN: | 1664-3224 78676053 |
| DOI: | 10.3389/fimmu.2024.1437176 |
| Popis: | IntroductionCurrently, no study has determined whether platelet transfusion refractoriness (PTR) post-hematopoietic stem cell transplantation (HSCT) before engraftment in patients with myelodysplastic syndrome (MDS) would impacts clinical outcomes.MethodsWe performed a MDS-specific retrospective analysis to determine whether PTR in one-month post-HSCT in patients with MDS could influence outcomes.Results and discussionAmong the 315 patients enrolled, 110 (34.9 %) had PTR from stem cell infusion to one-month post-HSCT. Baseline characteristics of the PTR and non-PTR groups were similar. We found that patients with PTR had a slower and lower rate of platelet engraftment by day 28, as well as a slower recovery of neutrophils. The median days of neutrophil and platelet engraftment were 14 days (9-23) and 17 days (8-28) in the PTR groups versus 13 days (9-23) and 15 days (7-28) in the non-PTR group (P1041ng/ml (median level) were independent adverse factors of platelet engraftment. |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|